- Home
- ACP vs REPL Comparison
ACP vs REPL Comparison
Compare ACP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACP
- REPL
- Stock Information
- Founded
- ACP 2010
- REPL 2015
- Country
- ACP United States
- REPL United States
- Employees
- ACP N/A
- REPL N/A
- Industry
- ACP Investment Managers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- ACP Finance
- REPL Health Care
- Exchange
- ACP Nasdaq
- REPL Nasdaq
- Market Cap
- ACP 695.1M
- REPL 578.4M
- IPO Year
- ACP N/A
- REPL 2018
- Fundamental
- Price
- ACP $5.83
- REPL $8.98
- Analyst Decision
- ACP
- REPL Strong Buy
- Analyst Count
- ACP 0
- REPL 6
- Target Price
- ACP N/A
- REPL $20.00
- AVG Volume (30 Days)
- ACP 337.9K
- REPL 1.6M
- Earning Date
- ACP 01-01-0001
- REPL 05-22-2025
- Dividend Yield
- ACP 17.79%
- REPL N/A
- EPS Growth
- ACP N/A
- REPL N/A
- EPS
- ACP N/A
- REPL N/A
- Revenue
- ACP N/A
- REPL N/A
- Revenue This Year
- ACP N/A
- REPL N/A
- Revenue Next Year
- ACP N/A
- REPL N/A
- P/E Ratio
- ACP N/A
- REPL N/A
- Revenue Growth
- ACP N/A
- REPL N/A
- 52 Week Low
- ACP $5.55
- REPL $4.93
- 52 Week High
- ACP $7.17
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- ACP 54.56
- REPL 53.81
- Support Level
- ACP $5.68
- REPL $8.25
- Resistance Level
- ACP $5.93
- REPL $9.53
- Average True Range (ATR)
- ACP 0.07
- REPL 0.88
- MACD
- ACP -0.00
- REPL 0.17
- Stochastic Oscillator
- ACP 58.00
- REPL 71.10
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.